BioCentury | Nov 12, 2020

Nov. 11 Quick Takes: Adagio raises $80M for COVID-19 antibody; plus venture investments for Congenica, CoImmune, Trailhead, Doer Biologics, Protomer and more

...into Biocon BiologicsBiocon Ltd. (NSE:BIOCON; BSE:532523) said its Biocon Biologics Ltd. biosimilars unit will receive a Rs1,125...
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

This article has been updated to reflect that the Indian health ministry did not include Alzumab itolizumab among the drugs on its COVID-19 treatment protocol. With an Indian EUA for Alzumab, Biocon is now planning...
BioCentury | Jan 4, 2020
Product Development

More Waves to come on stereopure antisense oligo tech

Though the first clinical readouts from Wave’s antisense oligo platform disappointed investors, the company thinks it can parlay the learnings into improved efficacy. 2020 will offer more data readouts to support or refute the company’s...
BioCentury | Dec 30, 2019
Clinical News

Huntington data quell fears about Wave's platform, but leave plenty to prove

The latest data from Wave allayed some doubts about the company’s stereopure oligonucleotide platform, but suggested that the biotech has yet to prove it can generate a competitive product. The company plans to double the...
BioCentury | Dec 16, 2019
Product Development

Wave crashes on DMD data as investors await Huntington’s readout

Wave’s decision to discontinue its two Duchenne muscular dystrophy programs raised broader investor concerns about the company’s stereopure oligonucleotide platform and sent shares down more than 50% on Monday. Another readout for the platform in...
BioCentury | Oct 5, 2019

Seeking bright spots in 4Q19 amid continued underperformance

Biotech watchers are hoping a busy fourth quarter of data readouts, regulatory actions and IPOs will provide some bright spots to counteract the sector’s continued overall underperformance, which is not expected to improve in 2020....
BioCentury | Sep 4, 2019
Company News

Management tracks: PhRMA, Arcus, Beam, Stealth, Bolt, Athenex, Click, Melinta, Kallyope and Genor

PhRMA said that Giovanni Caforio, who was chairman-elect, will become chairman of PhRMA's board. Caforio is chairman and CEO of Bristol-Myers Squibb Co. (NYSE:BMY) and succeeds Olivier Brandicourt, who stepped down as CEO of Sanofi...
BioCentury | Jul 26, 2019

Earnings on deck

Earnings on deck At least 27 profitable biotechs and pharmas are slated to report earnings this week. (A) During market hours in Europe, premarket on U.S. exchanges; (B) Fiscal 1Q Company Date Pre/post mkt 2Q19...
BioCentury | Jul 25, 2019
Financial News

July 25 Financial Quick Takes: Livongo, Castle pop after IPOs; plus a K2HV-Evelo deal, earnings beats for AZ & Roche, and more

Livongo, Castle rise in first trading day Livongo Health inc. (NASDAQ:LVGO) and Castle Biosciences Inc. (NASDAQ:CSTL) each posted gains in their first day of trading Thursday after pricing upsized IPOs. Digital health play Livongo added...
BioCentury | Apr 12, 2019
Clinical News

Wave down on delay for Huntington disease readouts

Wave lost $7.84 (19%) to $33.91 on April 10 after it said top-line data from two Phase Ib/IIa trials of its antisense oligonucleotide therapies for Huntington disease will be delayed until year end due to...
Items per page:
1 - 10 of 586